3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
80
Colonic Neoplasms
18
Neoplasm Metastasis
17
Rectal Neoplasms
14
Neoplasms
13
Stomach Neoplasms
7
Carcinoma, Non-Small-Cell Lung
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Gastrointestinal Neoplasms
4
Carcinoma, Renal Cell
3
Carcinoma, Neuroendocrine
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
Brain Neoplasms
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Unresectable Metastatic Colorectal Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ras-mutated Metastatic Colorectal Cancer
1
Prostatic Neoplasms
1
Interventions
spartalizumab
1
sapropterin
1
penpulimab
1
niraparib
1
anlotinib
1
Taxes
1
Leucovorin
1
Ipilimumab
1
IFL protocol
1
Gemcitabine
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pancreatic Adenocarcinoma Metastatic
×
IFL protocol
×
Clear all
NCT06747845
2025-09-16
ParpVax2
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
68 enrolled